玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究

摘要

目的 探讨玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发非缺血性黄斑水肿的疗效和安全性.方法 回顾分析临床确诊的BRVO继发非缺血性黄斑水肿患者50例(50眼),依据手术情况将患者分为2组,康柏西普组26例(26眼)患者接受按需治疗的玻璃体内注射,光凝组24例(24眼)患者接受标准的黄斑区格栅样光凝治疗黄斑水肿.2组分别于术后l周、1个月、2个月、3个月进行复查,观察患者的最佳矫正视力(best-correctedvisual acuity,BCVA)和黄斑中心凹厚度(central macular thickness,CMT)的变化.对比分析2组患眼治疗前后BCVA、CMT的变化,并观察眼部和全身并发症的发生情况.结果 治疗前2组患者的BCVA差异无统计学意义(P＞0.05).康柏西普组和光凝组治疗后1周、1个月、2个月、3个月时BCVA均较治疗前提高,差异均有统计学意义(均为P＜0.05);康柏西普组与光凝组治疗后1周、1个月、2个月、3个月时组间比较均较高,差异均有统计学意义(均为P＜0.05).术后3个月,康柏西普组18眼(69.23％)视力提高2行以上;光凝组8眼(33.33％)视力提高2行以上.治疗前2组患者的CMT组间比较,差异无统计学意义(P＞0.05).康柏西普组和光凝组治疗后l周、1个月、2个月、3个月时CMT均较术前减小,差异均有统计学意义(均为P＜0.05).康柏西普组与光凝组治疗后1周、1个月、2个月、3个月时2组间CMT比较均较小,差异均有统计学意义(均为P＜0.05).康柏西普组首次注药后随访3个月,11眼行重复注射.其中1个月后CMT＞ 250 μm重复注射2眼,2个月后重复注射7眼,3个月后重复注射2眼.随访期间50眼均未发生与药物、玻璃体内注射相关的全身不良反应.注射后出现局部球结膜下出血7眼.结论 康柏西普治疗BRVO继发的非缺血性黄斑水肿术后视力提高的程度和黄斑区视网膜水肿减轻的程度均优于黄斑区格栅样光凝治疗.%Objectlve To assess the clinical effects and safety of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion (BRVO).Methods A total of 50 patients (50 eyes) with non-ischemic macular edema following BRVO were retrospectively analyzed.Patients were divided into 2 groups:ICI group (26 eyes) received intravitreal injection of conbercept,laser group (24 eyes) received standard-of-care grid laser for macular edema.The best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and 1 week,1 month,2 months and 3 months after treatment.Then,the changes in pre-treatment and post-treatment were compared,and the related complications were recorded.Results The difference of BCVA before treatment was not significant between two groups (P ＞ 0.05).BCVA at 1 week,1 month,2 months and 3 months after treatment in two groups were all improved,the differences were statistically significant compared with before treatment (all P ＜ 0.05),and the differences were statistically significant between two groups after treatment (all P ＜0.05).At 3 months after treatment,BCVA of 18 patients (69.23％) in ICI group and 8 patients (33.33％) in ICI group improved 2 lines.The difference of CMT before treatment was not significant between two groups (P ＞ 0.05),CMT at 1 week,1 month,2 months and 3 months after treatment in two groups were all decreased,the differences were statistically significant compared with before treatment (all P ＜ 0.05),and the differences were statistically significant between two groups after treatment (all P ＜0.05).13 eyes received repeat intravitreal injection in ICI group,including 2 eyes at 1 month,7 eyes at 2 months with CMT ＞250 μm,and 3 eyes at 3 months.No severe side effect related with drug and intravitreal injection occurred in the two groups.Conclusion Mean BCVA change and CMT change are significantly greater in the intravitreal injection of conbercept than the standard-of-care grid laser group for the macuiar edema secondary to non-ischemic BRVO.